摘要
目的为进一步提高中晚期肝癌的治疗效果，采用综合序贯介入治疗，并对其疗效进行分析。方法３６例原发性肝癌，综合治疗组１６例，肝功能ＣｈｉｌｄＡ级１０例，Ｂ级６例。癌块＜５ｃｍ者１例，＞５ｃｍ者１５例，合并门脉癌栓者７例。肝动脉栓塞化疗（ＴＡＥ）组２０例，ＣｈｉｌｄＡ级及Ｂ级各１０例，癌块＜５ｃｍ者２例，＞５ｃｍ者１８例，门脉癌栓７例。ＴＡＥ组按常规行ＴＡＥ治疗。综合治疗组的措施是：ＴＡＥ．Ｂ超引导下门静脉栓塞化疗、无水乙醇肝内注射（ＰＥＩ）、Ｂ超引导下门脉癌栓的无水乙醇注射治疗、碘油及化疗药物肝内直接注射、其他措施有免疫制剂及９０Ｙ－玻璃微球肝内注射等，以上治疗序贯进行。结果随访时间３年，综合治疗组病程４～３４个月，最长生存湖３４个月（存活），半年生存率为８７．５％，一年生存率为５６．２％．ＴＡＥ组病程３－２９个月，最长生存期２９个月（死亡）。半年生存率为６０．０％，一年生存率为２０．４％。结论综合序贯治疗的半年及一年生存率均较单纯ＴＡＥ组显著延长，在改善肝癌预后上起重要作用。
Objectives To increase further the theraputic effects of primary liver cancer (PLC) in its advanced stage, combination and sequencial interventional treatment procedure were adopted. Methods Among thirty-six PLC patients, there were sixteen in combination treatment group, liver function of Child A in ten, Child B in six. Tumor mass<5cm in one, >5cm in 15. There were seven cases accompanied by portal vein thrombus. Among twenty patients in TAE treatment group, there were ten in each with liver function of Child A and Child B. Tumor mass < 5cm in two and >5cm in eighteen, in seven with portal thrombi. The routine method was used in TAE treatment group. TAE percutaneous ethanol injection, percutaneous transhepa- tic portal chemoembolization, ethanol injection for portal venous thrombus and drugs injected directly into tumor mass were sequentially given in combination treatment group. Results In three years follow-up, the longest survival period was 34 months (still alive), the half-year and one-year were 87.5% and 56.2% respectively in combination group.In TAE group the longest survival period was 29 months, the half-year and one-year survival period were 60.6% and 20.4% respectively. Conclusions It indicates that combination and sequencial interventional treatment for PLC is beneficial in improving the prognosis. [
出处
《中华消化杂志》
CAS
CSCD
北大核心
1998年第1期13-15,共3页
Chinese Journal of Digestion
